Published on Medical Design Technology (https://www.mdtmag.com)

Home > InVivo targets $22B injectable pain-relief market | Regulatory Roundup

InVivo targets $22B injectable pain-relief market | Regulatory Roundup

InVivo Therapeutics engages the FDA to discuss the regulatory path for its injectable hydrogel for neurological pain, anticipating an annual market potential of $22 billion.

InVivo engages the FDA to move forward on injectable pain-relief hydrogen, aims for $22B yearly market [1]
InVivo Therapeutics [2] (OTC:NVIV [3]) is hoping to break into what may be a $22 billion annual market with its new combination injectable hydrogel for pain management in the lower back, legs, neck or arms.

Late last month, the company submitted a request to meet with the FDA's Office of Combination Products and the Center for Devices & Radiological Health to discuss the path for the product, a hydrogel engineered for sustained release of therapeutic molecules.

Content Item Type: 
News [4]
Meta Canonical URL: 
http://www.mdtmag.com/news/2012/07/invivo-targets-22b-injectable-pain-relief-market-regulatory-roundup
Summary: 

InVivo Therapeutics engages the FDA to discuss the regulatory path for its injectable hydrogel for neurological pain, anticipating an annual market potential of $22 billion.  InVivo engages the FDA to move forward on injectable pain-relief hydrogen, aims for $22B yearly market News Well, 510(k), Food & Drug Administration (FDA), Pain Management, Regulatory/Complianceread more

Contributed Author: 
Mass Device
Legacy NID: 
108 411

Deeper Insights

<% if ( rc.ss_related_image_url != null ){ %>
?cmpid=regwallcontent&utm_source=Deeper%20Insights">">
<% } %>

?cmpid=regwallcontent&utm_source=Deeper%20Insights" + ""><%- rc.label %>

<% if ( rc.ss_search_logo != null ){ %> <% } %>
Advertisement
googletag.cmd.push(function() { googletag.display("dfp-ad-clone_of_wallpaper"); });
(function() { var _fbq = window._fbq || (window._fbq = []); if (!_fbq.loaded) { var fbds = document.createElement('script'); fbds.async = true; fbds.src = '//connect.facebook.net/en_US/fbds.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(fbds, s); _fbq.loaded = true; } _fbq.push(['addPixelId', '745881082149515']); })(); window._fbq = window._fbq || []; window._fbq.push(['track', 'PixelInitialized', {}]);
(function(d,s,i,r) { if (d.getElementById(i)){return;} var n=d.createElement(s),e=d.getElementsByTagName(s)[0]; n.id=i;n.src='//js.hs-analytics.net/analytics/'+(Math.ceil(new Date()/r)*r)+'/1743435.js'; e.parentNode.insertBefore(n, e); })(document,"script","hs-analytics",300000);
var _qevents = _qevents || []; (function() { var elem = document.createElement('script'); elem.src = (document.location.protocol == "https:" ? "https://secure" : "http://edge") + ".quantserve.com/quant.js"; elem.async = true; elem.type = "text/javascript"; var scpt = document.getElementsByTagName('script')[0]; scpt.parentNode.insertBefore(elem, scpt); })(); _qevents.push({ qacct:"p-jsEPJWTckjCbE" });
Quantcast
googletag.cmd.push(function () { googletag.display("dfp-ad-roadblock_modal"); });
googletag.cmd.push(function() { googletag.display("dfp-ad-roadblock_modal"); });
Source URL: https://www.mdtmag.com/news/2012/07/invivo-targets-22b-injectable-pain-relief-market-regulatory-roundup

Links
[1] http://www.businesswire.com/news/home/20120702005385/en/InVivo-Therapeutics-Engages-FDA-Product-Drug-Releasing
[2] http://www.massdevice.com/company/invivo-therapeutics-corp
[3] http://www.google.com/finance?q=OTC%3ANVIV
[4] https://www.mdtmag.com/content-item-types/news